Clinical experience with soluble TNF p75 receptor in rheumatoid arthritis

Seminars in Arthritis and Rheumatism

Volumn 29, Issue 3, 1999, Pages 172-181

  Franklin, C Michael ^a,b,c  

^a ABINGTON MEMORIAL HOSPITAL   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Rhematology Specialty Center   (United States)

Author keywords

Case studies; Disease modifying antirheumatic drugs; Etanercept; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ANTIRHEUMATIC AGENT; ETANERCEPT; PLACEBO; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; HUMAN; MALE; MORNING STIFFNESS; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS;

EID: 0033384879     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-0172(99)80028-6     Document Type: Article

References (44)

1. Wolfe F. The natural history of rheumatoid arthritis J Rheumatol 23 supp1 44 1996 13 22
2. Mitchell D.M. Spitz P.W. Young D.Y. Bloch D.A. McShane D.J. Fries J.F. Survival, prognosis, and causes of death in rheumatoid arthritis Arthritis Rheum 29 1986 706 714
3. Wolfe F. Mitchell D.M. Sibley J.T. Fries J.F. Bloch D.A. Williams C.A. The mortality of rheumatoid arthritis Arthritis Rheum 37 1994 481 494
4. Deleuran B.W. Cytokines in rheumatoid arthritis. Localization in arthritic joint tissue and regulation in vitro Scand J Rheumatol 25 suppl 104 1996 1 34
5. Starkebaum G. Role of cytokines in rheumatoid arthritis Science and Medicine 1998 6 15
6. Brennan F.M. Maim R.N. Feldmann M. Cytokine expression in chronic inflammatory disease Br Med Bull 51 1995 368 384
7. Saxne T. Palladino M.A. Jr Heinegård D. Talal N. Wollheim F.A. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum Arthritis Rheum 31 1988 1041 1045
8. Tucci M.A. Baker R. Mohamed A. Tsao A.K. Hughes J. Synovial tissues collected from rheumatoid patients undergoing total joint arthroplasty express markers for acute inflammation Biomed Sci Instrum 34 1997 169 174
9. Buchan G. Barrett K. Fujita T. Taniguchi T. Maini R. Feldmann M. Detection of activated T cell products in the rheumatoid joint using cDNA probes to interleukin-2 (IL-2) IL-2 receptor and IFN-γ Clin Exp Immunol 71 1988 295 301
10. Fontana A. Hentgartner H. Fehr K. Grob P.J. Cohen G. Interleukin-1 activity in the synovial fluid of patients with rheumatoid arthritis Rheumatol Int 2 1982 49 56
11. Pettipher E.R. Higgs G.A. Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint Proc Natl Acad Sci USA 83 1986 8749 8753
12. Saklatvala J. Sarsfield S.J. Townsend Y. Pig interleukin 1. Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, andfever J Exp Med 162 1985 1208 1222
13. Carroll G. Bell M. Wang H. Chapman H. Mills J. Antagonism of the IL-6 cytokine subfamily—a potential strategy for more effective therapy in rheumatoid arthritis Inflamm Res 47 1998 1 7
14. Brennan F.M. Chantry D. Jackson A. Maini R. Feldmann M. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis Lancet 2 1989 244 247
15. Haworth C. Brennan F.M. Chantry D. Turner M. Maini R.N. Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α Eur J Immunol 21 1991 2575 2579
16. Butler D.M. Feldmann M. Di Padova F. Brennan F.M. p55 and p75 tumor necrosis factor receptors are expressed and mediate common functions in synovial fibroblasts and other fibroblasts Eur Cytokine Netw 5 1994 441 448
17. Keffer J. Probert L. Cazlaris H. Georgopoulos S. Kaslaris E. Kioussis D. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis EMBO J 10 1991 4025 4031
18. Joosten L.A.B. Helsen M.M.A. van de Loo F.A.J. van den Berg W.B. Anticytokine treatment of established type II collageninduced arthritis in DBA/1 mice. A comparative study using anti-TNFa, anti-IL-Ice/β, and IL-IRa Arthritis Rheum 39 1996 797 809
19. Wooley P.H. Dutcher J. Widmer M.B. Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice J Immunol 151 1993 6602 6607
20. Drevlow B.E. Lovis R. Haag M.A. Sinacore J.M. Jacobs C. Blosche C. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis Arthritis Rheum 39 1996 257 265
21. Bresnihan B. Lookabaugh J. Witt K. Musikic P. Treatment with recombinant human interleukin-1 receptor antagonist (rhIL-lra) in rheumatoid arthritis (RA): results of a randomized double-blind,placebo-controlled multicenter trial [abstract] Arthritis Rheum 39 1996 S73
22. Arend W.P. Malyak M. Guthridge C.J. Gabay C. Interleukin-1 receptor antagonist: role in biology Annu Rev Immunol 16 1998 27 55
23. Wendling D. Racadot E. Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody J Rheumatol 20 1993 259 262
24. Elliott M.J. Maini R.N. Feldmann M. Kalden J.R. Antoni C. Smolen J.S. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis Lancet 344 1994 1105 1110
25. Elliott M.J. Maini R.N. Feldmann M. Long-Fox A. Charles P. Bijl H. Repeated therapy with monoclonal antibody to tumour necrosis factor a (cA2) in patients with rheumatoid arthritis Lancet 344 1994 1125 1127
26. Mohler K.M. Torrance D.S. Smith C.A. Goodwin R.G. Stremler K.E. Fung V.P. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists J Immunol 151 1993 1548 1561
27. Moreland L.W. Baumgartner S.W. Schiff M.H. Tindall E.A. Fleischmann R.M. Weaver A.L. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein N Engl J Med 337 1997 141 147
28. Moreland L.W. Schiff M.H. Baumgartner S.W. Tindall E.A. Fleischmann R.M. Bulpitt K.J. Etanercept therapy in rheumatoid arthritis: a randomized controlled trial Ann Intern Med 130 1999 478 486
29. Weinblatt M.E. Kremer J.M. Bankhurst A.D. Bulpitt K.J. Fleischmann R.M. Fox R.I. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receivingmethotrexate N Engl J Med 340 1999 253 259
30. Bannwarth B. Labat L. Moride Y. Schaeverbeke T. Methotrexate in rheumatoid arthritis. An update Drugs 47 1994 25 50
31. [abstract] Moreland L.W. Baumgartner S.W. Schiff M.H. Tindall E.A. Fleischmann R.M. Weaver A.L. Optimal dose of TNF receptor p75 Fc fusion protein (TNFR:Fc, Enbrel™ (Abstract 157) Arthritis Rheum 41 9 suppl 1998 S59
32. Felson D.T. Andersen J.J. Boers M. Bombardier C. Furst D. Goldsmith C. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis Arthritis Rheum 38 1995 477 484
33. Paulus H.E. Egger M.J. Wand J.R. Williams H.J. The Cooperative Systematic Studies of Rheumatic Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo Arthritis Rheum 33 1990 477 484
34. [abstract] Moreland L.W. Baumgartner S.W. Tindall E.A. Schiff M.H. Fleischmann R.M. Weaver A.L. Longterm safety and efficacy of TNF receptor (p75) Fc fusion protein (TNFR:Fc; Enbrel™) in DMARD refractory rheumatoid arthritis (RA) [slide presentation handout] (Abstract 1987) Arthritis Rheum 41 9 suppl 1998 S364
35. [poster] Moreland L.W. Baumgartner S.W. Tindall E.A. Schiff M.H. Fleischmann R.M. Weaver A. Longterm treatment of DMARD failing rheumatoid arthritis patients with TNF receptor p75 Fc fusion protein (TNFR:Fc; ENBREL™) 1998
36. Hawley D.J. Wolfe F. Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable asmeasures of rheumatoid arthritis outcome: analysis of 122 studies J Rheumatol 18 1991 1008 1014
37. Pincus T. Marcum S.B. Callahan L.F. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: 11. Second line drugs and prednisone J Rheumatol 19 1992 1885 1894
38. Enbrel® [manufacturer's prescribing information] 1999 Immunex Corp Seattle, WA
39. [abstract] McCabe D. Moreland L. Caldwell J. Sack M. Weisman M. Edwards C.K.I. A phase I/11 study to evaluate the safety, immunogenicity pharmacokinetics and potential efficacy of IV rHuTNF binding protein pegylated dimer (TNFbp) in patients with active RA (Abstract 154) Arthritis Rheum 41 9 suppl 1998 S58
40. Wolfe F. Adverse drug reactions of DMARDs and DC-ARTs in rheumatoid arthritis Clin Exp Rheumatol 15 suppl 17 1997 S75 S81
41. Fuchs H.A. Kaye J.J. Callahan L.F. Nance E.P. Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease J Rheumatol 16 1989 585 591
42. Wilke W.S. Sweeney T.J. Calabrese L.H. Early, aggressive therapy for rheumatoid arthritis: concerns, descriptions, and estimate of outcome Semin Arthritis Rheum 23 1993 26 41
43. van der Heide A. Jacobs J.W.G. Bijlsma J.W.J. Heurkens A.R.M. van Booma-Frankfort C. van der Veen M.J. The effectiveness of early treatment with “second-line” antirheumatic drugs. A randomized, controlled trial Ann Intern Med 124 1996 699 707
44. Furst D.E. Koehnke R. Burmeister L.F. Kohler J. Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis J Rheumatol 16 1989 313 320